February 22nd 2025
Phase 3 WAYPOINT trial shows tezepelumab significantly reduces nasal polyp severity, congestion, and surgery needed in severe chronic rhinosinusitis with nasal polyp.
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management
April 3, 2025
Register Now!
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
How BTK Inhibitors Differ From Current CSU Treatment Approaches
February 20th 2025Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors offer a novel upstream approach, in contrast to current treatments that work downstream by either blocking released mediators (antihistamines), neutralizing circulating IgE (omalizumab), or broadly suppressing immune responses (immunosuppressants).